Clinical Trials in Diabetes (Read More)

However, every golden opportunity is always plagued with obstacles.  Years and millions have been invested in developing the right drug, yet you’re faced with the ongoing burden of… patient recruitment, site selection, and regulations – just a handful of the challenges faced that have the potential  to threaten the success of your drug.  Attend the first conference of this kind to tackle these challenges and ensure you are adhering to a cost efficient yet sustainable process

GSK was fined GBP 1.9 billion for marketing Avandia (3), which was withdrawn due to the attributed cardiovascular risk that were a result of poor trial design (4).  Is this cost worth it? No; which is why it is critical to get every aspect of your clinical trial right. Would you like to market your blockbuster with hitch-free trials? Yes

The competition is tight, every minute you lose determining how to be efficient yet comply with regulations is time lost in the race to success

So make sure you get ahead of the game; learn tips and techniques from the opinion leaders in Diabetes…and book now

Key topics:

• Patient recruitment and retention that will reduce costly delays due to drop-outs and slow recruitment campaigns
  
• Effective trial design that will incorporate the cardiovascular endpoints that will minimise cost but ensure approval
  
• Managing CROs and working towards partnerships between pharmaceutical companies for optimal drug development and trial outcome
  
• Trial planning and implementation in Emerging Markets that will improve trial outcome

(1) Henley, J. (2011). Diabetes: the epidemic. The Guardian.

(2) Kevin Fickenscher, MD on twitter: http://twitter.com/#!/mdkev

(3) Drug company fined for Avandia marketing. Nov. 7, 2011. Diabetes.co.uk:

http://www.diabetes.co.uk/news/2011/Nov/drug-company-fined-for-avandia-marketing-96123537.html

(4) Gale, Edwin A.M. (2011). Therapy: The second time as farce: rosiglitazone and the regulators. Nature Reviews Endocrinology. Vol. 7; p. 5-6